ABT.N
Latest Trade
106.66USDChange
0.96(+0.91%)Volume
1,629,701Today's Range
-
106.7552 Week Range
-
114.19As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 105.70 |
|---|---|
Open | 104.80 |
Volume | 1,629,701 |
3M AVG Volume | 111.90 |
Today's High | 106.75 |
Today's Low | 104.51 |
52 Week High | 114.19 |
52 Week Low | 61.62 |
Shares Out (MIL) | 1,770.53 |
Market Cap (MIL) | 187,145.00 |
Forward P/E | 32.88 |
Dividend (Yield %) | 1.36 |
Abbott Laboratories- Freestyle Libre 2 Now Available To Medicare Patients
Abbott Receives FDA Approval For Ios-Compatible App Allowing People Living With Chronic Pain And Movement Disorders To Personalize Therapy Via Their Mobile Device
Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry
Medical Equipment & Supplies
Contact Info
100 Abbott Park Rd
ABBOTT PARK, IL
60064-3500
United States
+1.224.6676100
https://www.abbott.comExecutive Leadership
Miles D. White
Executive Chairman of the Board
Robert B. Ford
President, Chief Executive Officer, Chief Operating Officer, Director
Robert E. Funck
Chief Financial Officer, Executive Vice President - Finance
Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Mary K. Moreland
Executive Vice President of Human Resources
Price To Earnings (TTM) | 61.14 |
|---|---|
Price To Sales (TTM) | 5.95 |
Price To Book (MRQ) | 6.12 |
Price To Cash Flow (TTM) | 29.97 |
Total Debt To Equity (MRQ) | 64.36 |
LT Debt To Equity (MRQ) | 59.47 |
Return on Investment (TTM) | 5.28 |
Return on Equity (TTM) | 4.49 |
Broadmark Realty Capital Inc, a real estate investment trust (REIT), has appointed former Ventas Inc attorney Nevin Boparai as its chief legal officer as the coronavirus pandemic shakes up the market for commercial space.
U.S. Patent and Trademark Office administrative judges can review a patent that the office's director Andrei Iancu litigated while in private practice, a federal appeals court said on Wednesday, rejecting an argument that their loyalty to him might cloud their judgment.
The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories <ABT.N> last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a...
The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing...
The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of U.S. states and territories to support school reopening and other critical tasks, an administration official said at a press...
Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.
The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories <ABT.N> for about $750 million, a White House spokeswoman said on Thursday.
The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said on Thursday.
Abbott Laboratories <ABT.N> said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.
Abbott Laboratories said on Wednesday it won U.S. marketing approval for a COVID-19 portable test that can deliver results within 15 minutes.
Abbott Laboratories <ABT.N> expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.
Abbott Laboratories <ABT.N> said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.
* ABBOTT CEO SAYS AT THE END OF JUNE, PROCEDURE VOLUMES REBOUNDED TO 90% OF PRE-CRISIS LEVELS ON AVERAGE IN U.S. - CONF CALL
Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.
Abbott Laboratories on Thursday reported a 46.6% fall in second-quarter profit as the COVID-19 pandemic continued to batter its medical device unit.
* ABBOTT RECEIVES FDA APPROVAL FOR NEW HEART RHYTHM DEVICES FEATURING BLUETOOTH CONNECTIVITY AND CONTINUOUS REMOTE MONITORING Source text for Eikon: Further company coverage:
* ABBOTT - COS PARTNER TO INTEGRATE ABBOTT'S FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING TECHNOLOGY WITH TANDEM'S INSULIN DELIVERY PRODUCTS Source text for Eikon: Further company coverage:
* ABBOTT LABORATORIES FILES FOR POTENTIAL 2-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/3hT6Zrw) Further company coverage:
* ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/3i0wEim) Further company coverage:
The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.